Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Home Genotype-RX Genotype-Pheno Genotype-Clinical HIVdb Program

Integrase Inhibitor Resistance Notes

Last updated on Sep 15, 2009
Resistance Matrix Resistance Mutation Comments Resistance Mutation Scores                                  
Integrase Inhibitor (INI) Resistance Mutations
 6692121138140143147148153155263
ConsTEFEGYSQSNR
Raltegravir† QYAKASRCHGHRK HS 
Elvitegravir§IAKQYAKAS GHRKYHSK
LEGEND INI-resistance mutations selected in persons receiving raltegravir (D Hazuda HIVDRW 2007, I Malet AAC 2008) or elvitegravir (D McColl HIVDRW 2007) are characterized for in vitro susceptibility (G Jones CROI 2007, D McColl HIVDRW 2007, C Ren HIVDRW 2007, M Rowley Prog Med Chem 2008). Mutations in bold red are associated with >5-10 fold decreased susceptibility.
† Other mutations selected in vitro or in vivo by raltegravir include L74M, T97A, V151I, E157Q, G163R, I203M, and S230R/N.
§ Other mutations selected in vitro or in vivo by elvitegravir include the nonpolymorphic mutations H51Y, Q95K, H114Y, P145S, and Q146P (K Shimura JV 2007).
ADDITIONAL MUTATIONS Additional integrase mutations selected by other investigational INIs include the nonpolymorphic mutations T125K, A128T, Q146K, N155S, K160D, and the polymorphic mutations V72I, A154I, V165I, and V201I (M Lataillade AVT 2007).

Team

Resources